



Certificate of Mailing/Transmission (37 C.F.R. § 1.8):

Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: May 21, 2003 Name of Person Certifying: Peggy Nichols
Printed Name: Peggy Nichols

RECEIVED
MAY 30 2003
TECH CENTER 1600/2300

Docket No. GZ 2104.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Charles A. Nicolette

Filing Date: August 17, 2001

Examiner: Not Yet Assigned

Serial No.: 09/931,969

Group Art Unit: 1614

Title: THERAPEUTIC COMPOUNDS FOR OVARIAN CANCER

RESPONSE TO NOTICE TO COMPLY AND PRELIMINARY AMENDMENT

Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

On May 9, 2003, the U.S. Patent and Trademark Office issued a Withdrawal of Previously Sent Notice (copy attached) in connection with the above-identified application. The May 9, 2003 Notice indicated that the Notice mailed on May 10, 2002 (Filing Receipt) is withdrawn for failure to comply with the Sequence Rules, 37 C.F.R. §§ 1.821-1.825. A response to the May 9, 2003 Notice is due June 9, 2003. Accordingly, this reply is timely filed.

The May 9, 2003 Notice indicated that the application was incomplete because pages 21 and 22 of the specification contained sequences without corresponding sequence identifiers. In response to the Notice and prior to examination of the subject application, Applicant respectfully request consideration and entry of the following amendments:

Please substitute the enclosed pages 21 and 22 of the specification:

culture may not be completely identical (morphologically, genetically, or phenotypically) to the parent cell. By "expanded" is meant any proliferation or division of cells.


A "composition" is intended to mean a combination of active agent and another compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant.

A "pharmaceutical composition" is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use *in vitro*, *in vivo* or *ex vivo*.

10 As used herein, the term "pharmaceutically acceptable carrier" encompasses any
of the standard pharmaceutical carriers, such as a phosphate buffered saline solution,
water, and emulsions, such as an oil/water or water/oil emulsion, and various types of
wetting agents. The compositions also can include stabilizers and preservatives. For
examples of carriers, stabilizers and adjuvants, see Martin REMINGTON'S PHARM. SCI.,
15 15th Ed. (Mack Publ. Co., Easton (1975)).

An “effective amount” is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages. The present invention provides compounds having the following structures:

20 FLTDERMPV (SEQ ID NO: 3)
FLTDERMPV




(Page 21 as amended)


Page 2

Serial No. 09/931,969
Docket No.: GZ 2104.00
GZ Ref.: 5040US

FLTDEARSV (SEQ ID NO: 5)
FLTDEARSV




FLDDEIMRV (SEQ ID NO: 7)
~~FLDDEIMRV~~




5

FLDDEITFV (SEQ ID NO: 9)
FLDDEITFV



10

HEDDRLPV (SEQ ID NO: 11)
-HEDDRLPV-



(Page 22 as amended)

The five structures listed on pages 21 and 22 have been amended to include sequence numbers in the classification of the structures. Support for these amendments is found on pages 4 and 5 of the specification as originally filed. An issue of new matter is not raised by these amendments and entry thereof is respectfully requested.

The Notice also requested an initial or substitute computer readable form (CRF) copy of the "Sequence Listing" and an initial or substitute paper copy of the "Sequence Listing" as well as any amendment directing its entry into the specification. Applicant's attorney, on behalf of Applicant, hereby respectfully requests waiver of submission of the above-noted items on the ground that they have been previously submitted (see attached copy of postcard receipt showing acceptance of these items on April 8, 2002 by the U.S. Patent Office). The amendments to pages 21 and 22 of the specification do not alter the sequence listing and thus, a substitute listing is not required.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any fee is required, authorization is given to charge the cost of fee to **Deposit Account No. 50-2518**, billing reference number **19442-7235**.

Respectfully submitted,

Date: May 21, 2003

By: 
Antoinette F. Konski
Reg. No. 34,202

Bingham McCutchen, LLP
Three Embarcadero Center, Suite 1800
San Francisco, CA 94111
Telephone: (650) 849-4950
Telefax: (650) 849-4800